Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Lymphoma 6Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2

Interventions

sapanisertib 2tovorafenib 1serabelisib 1pevonedistat 1Paclitaxel 1MLN 8237 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Nonhematologic Malignancies × MLN 8237 × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡